Leo Mavely is the CEO of
Axio
Biosolutions
a medtech company focused on military
medicine and surgical solutions. Axio developed Axiostat –
India’s First and only USFDA approved trauma hemostat that
stops life threatening bleeding instantly.
Axiostat
is is being used by soldiers in over 350
battallions across India to manage bleeding from injuries
in battlefield. It is approved in over 40 countries and
used by major armed forces globally.
A
bioengineer by qualification, Leo invented the core
technology of Axio and has been instrumental in building
Axio soon after college during his tenure at Nirmalabs.
Leo holds multiple patents and publications in the field
of novel biomaterials for medical tech applications.
Leo was
featured in the list of 40 under 40 emerging business
leaders by Fortune Magazine consecutively in 2016, 2017,
2018 and 2019 and in the list of 35 under 35 entrepreneurs
by Entrepreneur magazine in 2020. Leo was honored as
Çhampions of Change by Prime minister, Sh Narendra Modi in
2017. He was the recipient of Silicon valley challenge
2014, Anjani Mashelkar Inclusive Innovation Award 2013,
CNBC Samsung Social Innovation Award 2012 and was invited
speaker at Indian Science congress 2010.
Axio
Biosolutions Private Limited is medtech startup focused on
Military medicine, Surgical solutions and Advanced wound
care. Axiostat® its flagship product which was developed
by its Founder - Leo Mavely to reduce the mortality due to
traumatic bleeding from life threatening injuries.
Axiostat® is being widely used by Military, Hospitals,
Ambulance services, Industries, Relief aid and is part of
standard field kit of defence forces in India. Axiostat
has been instrumental in helping save lives of soldiers
during surgical strike – 2016 and also continue to support
humanitarian missions during recent European conflicts.
Axiostat® has also received the prestigious European CE
approval, USFDA approval and is being exported to 40+
countries. It was recently launched in hospitals in United
States and is the first Indian medical device – hemostat
to do so. Axio has raised over $20mn USD in venture
funding from Accel Partners, Ratan Tata’s UC-RNT Fund,
Omidyar network, Chiratate venture and TrueScale capital.
Axio has its state of the art R&D and manufacturing
facility at Ahmedabad, Gujarat and Corporate office at
Bengaluru, India.